Streetwise Articles



RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >


Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
Source: The Life Sciences Report  (2/22/17)
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. More >


0

Investing in Life Sciences Under the Trump Presidency
Source: Kristin McFarland for The Life Sciences Report  (2/16/17)
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. More >


Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report  (2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >


Bob Moriarty

Luminor Drives the Scout DS Forward
Source: Bob Moriarty for The Life Sciences Report  (2/6/17)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. More >


The Future of Cannabis Investing
Source: Tom Beck for Streetwise Reports  (2/3/17)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. More >


ContraVir's Hep B Drug Could Be a Game Changer
Source: The Life Sciences Report  (2/1/17)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. More >


Colin Lee Novick

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report  (2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >


Inovio's Zika Vaccine Generates Robust Immune Responses
Source: The Life Sciences Report  (1/25/17)
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. More >


2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report  (1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >


Jason Napodano

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >


19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Source: The Life Sciences Report  (1/3/17)
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. More >


Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
Source: The Life Sciences Report  (12/21/16)
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. More >


VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
Source: The Life Sciences Report  (12/21/16)
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. More >


Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth
Source: The Life Sciences Report  (12/14/16)
3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements.
More >


Why the Canadian Marijuana Sector Is the Next Big Thing and Why Emblem Is Our Top Pick
Source: Gecko Research for Streetwise Reports  (12/8/16)
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick. More >


Reliq Health Technologies Pilots Remote Patient Monitoring Program
Source: The Life Sciences Report  (12/7/16)
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. More >


Can Biotech's Trump Bump Last?
Source: The Life Sciences Report  (12/2/16)
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. More >


Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
Source: The Life Sciences Report  (11/14/16)
By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. More >


Len Yaffe

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Source: Dr. Len Yaffe for The Life Sciences Report  (11/2/16)
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. More >


Len Yaffe

Exploring Solutions to Healthcare's Spending Crisis
Source: Dr. Len Yaffe for The Life Sciences Report  (10/19/16)
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures. More >


Analysts Keep Focus on DURECT's DUR-928
Source: The Life Sciences Report  (10/6/16)
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma. More >


Anthony Vendetti

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition
Source: The Life Sciences Report  (10/5/16)
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. More >


Bob Moriarty

Imagin, a Better Way to Detect Bladder Cancer
Source: Bob Moriarty for The Life Sciences Report  (9/20/16)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. More >


Regeneus Secures Government Funding for R&D
Source: The Life Sciences Report  (9/14/16)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. More >


Showing Results: 1 to 25 of 352 Next